Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma

Stopped early · Phase 2

Conditions studied: Oligodendroglioma, Adult

In brief

RATIONALE: Current therapies for adult recurrent/progressive oligodendrogliomas provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of childhood brain tumors. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on adult recurrent/progressive oligodendrogliomas.

Key facts

Study ID

NCT00003472

Run by

Burzynski Research Institute

People needed

13

Starts

1996-05-01

Expected to finish

2007-09-01

Last updated by the study team

2018-03-21

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Burzynski Clinic — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.